US3867518A - Radioimmunoassay for insulin - Google Patents

Radioimmunoassay for insulin Download PDF

Info

Publication number
US3867518A
US3867518A US339803A US33980373A US3867518A US 3867518 A US3867518 A US 3867518A US 339803 A US339803 A US 339803A US 33980373 A US33980373 A US 33980373A US 3867518 A US3867518 A US 3867518A
Authority
US
United States
Prior art keywords
insulin
radioimmunoassay
gel
percent
blood plasma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US339803A
Inventor
John William Coffey
Hans John Hansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Hoffmann La Roche Inc
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to US339803A priority Critical patent/US3867518A/en
Application granted granted Critical
Publication of US3867518A publication Critical patent/US3867518A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/815Test for named compound or class of compounds
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/815Test for named compound or class of compounds
    • Y10S436/817Steroids or hormones

Definitions

  • RADIOIMMUNOASSAY FOR INSULIN Inventors: John William Coffey, West Caldwell; Hans John Hansen, Allendale, both of NJ.
  • the invention as described hereinafter provides such a radioimmunoassay.
  • This invention relates to an improved radioimmunoassay for measuring the level of immunoreactive insulin in the body fluids, particularly blood plasma of animals and humans. More particularly, this invention relates to a radioimmunoassay for measuring immunoreactive insulin which can be completed within about three hours by utilizing zirconyl phosphate gel at a pH at which free insulin will not bind to it, i.e., at a pH of from 6.0.to 6.5, preferably 6.25, as the adsorbent for the insulin-antibody complex.
  • This invention is based upon the discovery that a radioimmunoassay for immunoreactive insulin in body fluids, preferably blood plasma can be completed within three hours when zirconyl phosphate gel (Z-gel) at a pH at which free insulin will not bind to it, i.e., at a pH of from 6.0 to 6.5, preferably pH 6.25 is used to adsorb antibody-bound insulin while leaving free insulin in solution.
  • Z-gel zirconyl phosphate gel
  • the method is accurate and reproducible and eliminates the need for utilizing carriers to which the antibody is coupled.
  • the accuracy is shown by a comparison to a solid phase commercial assay using carriers having antibody coupled thereto.
  • thirty-two samples of human blood plasma were assayed for immunoreactive insulin using the solid phase commercial assay and using the assay of this invention.
  • the results showed a statistically significant (p 0.01) coefficient of correlation between the two assays (0.998) indicating the assay of this invention is accurate.
  • the reproducibility of the assay of this invention is within 10 percent when duplicate samples are run.
  • the titration curve used to determine the proper dilution of anti-insulin antiserum for used in the radioimmunoassay. This is necessary in order to avoid having excess antibody present, causing readings which are too high.
  • the ideal is to have a dilution at which about half the labelled insulin is complexed with antiserum.
  • the curve is prepared by adding increasing dilutions of the antiserum, diluted with a buffer composition at pH 7.4.
  • a typical suitable buffer is composed of 0.04 M phosphate (prepared from NaH PO, and NaOH) containing 0.6 mM thimersal and 0.5 percent wt./vol. bovine serum albumin (BSA) to a constant amount of radioiodinated insulin I-insulin).
  • a typical suitable buffer composition utilized in the incubation mixtures for preparing the titration curve is 0.2 ml. of a 0.04 M phosphate buffer at pH 7.4, containing 0.6 mM thimersal, 0.5 percent wt./vol. BSA and 0.15 M NaCl.
  • the incubation buffer is mixed with 0.1 ml. of varying dilutions of the antiserum and 0.1 ml. l-insulin in an incubation test tube and the mixture is incubated at 37C. for 45 mins.
  • the reaction is stopped by the addition of 5 ml. of an ammonium acetate slurry of Z-gel at pH 6.0 to 6.5, preferably 6.25, to each tube followed by 10 ml.
  • the Z-gel slurry contains, on a volume basis, about 40-45 percent solids.
  • the contents of the tubes are mixed, then centrifuged to separate the Z-gel-antibody-insulin precipitate and assayed for radioactivity. The proper dilution of antiserum is determined from the curve and utilized in subsequent assays utilizing the antiserum.
  • the standard inhibition curve is used to determine the concentration of insulin in the test fluid as follows:
  • Standard inhibition curves are prepared using mixtures containing 0.1 ml. of a buffer at pH 7.4.
  • a typical buffer is composed of 0.04 M phosphate, containing 0.6 mM thimersal, 0.5 percent wt./vol. BSA and 0.15 M NaCl; 0.1 ml. of the appropriate dilution of antiserum and 0.1 ml. of a standard solution of bovine insulin, e.g., 1.0 to 10.0 uU in the same buffer.
  • the mixture is incubated for 2 hours at 37C. then 0.1 ml. of I- insulin is added to each tube and incubated 45 minutes at 37C. The incubation is terminated by the addition of 5 ml.
  • 0.1 MI. of blood plasma containing unknown amounts of insulin are treated in the same manner as the standards used to prepare the inhibition curve.
  • the amount of insulin in the plasma samples is determined by comparison to the standard inhibition curve. If the plasma samples contain very high levels of insulin, they are diluted with appropriate amounts of a buffer at pH 7.4, preferably composed of 0.04 M phosphate, 0.6
  • any inorganic buffer at pH 7.4 can be used provided its ionic strength is similar to that of the test fluid, e.g., blood plasma.
  • Phosphate buffers are preferred because of their ready accessibility.
  • EXAMPLE 1 Preparation of Radioiodinated Insulin Twenty-five ug. of insulin (25 ,ul) in 0.4 M phosphate buffer (pH 7.4) was mixed with a mixture of 5 mCi of Na l in 50 pl. of dilute NaOH at pH 8-11 and 10 1.1.1. of 0.3 M phosphate buffer, pH 7.4.
  • the reaction was stopped by adding 200 pg. ,ul.) of sodium metabisulfite in 0.05 M phosphate buffer pH 7.4. Then 0.2 ml. of 1 percent aqueous bovine serum albumin was added. The mixture was chromatographed on a 2.5 X 20 cm. column of Sephadex G-25, a hydrophilic water-insoluble cross-linked dextran polymer gel commercially available from AB Pharmacia, Uppsala, Sweden, which had been equilibrated at 4C. with 0.1 M Tris.HCl buffer, pH 7.4, containing 0.9 percent NaCl.
  • the column was eluted with the same Tris buffer at a flow rate of 0.5 ml./min. and 1.0 ml. fractions were collected into tubes containing 1 ml. of 1 percent bovine serum albumin. The amount of radioactivity in a ul. aliquot of each fraction was determined and the fraction near the void volume of the column containing the largest amount of radioactivity was used as the source of l-insulin for the assay after dilution with a 0.04 M phosphate buffer at pH 7.4 containing 0.6 mM thimersal and 0.5 percent wt./vol. BSA until 1 ml of the diluted solution contains about-450,000 cpm/ml. of
  • distilled water was added to a volume of 15 liters and enough concentrated acetic acid was added to make the gel slurry 0.1 M with respect to acetic acid.
  • the gel was allowed to settle for 2 days in this solution after which the supernatant fluid was removed as completely as possible by aspiration.
  • the Z-gel slurry remaining had a volume of approximately 3 to 4 liters and was adjusted to pH 6.25 with concentrated ammonium hydroxide.
  • the resulting slurry contained, on a volume basis, about 40 to 45 percent solids.
  • EXAMPLE 3 Preparation of Titration Curve lnto five incubation test tubes 0.2 ml. of a 0.04 M phosphate buffer at pH 7.4 containing 0.6 mM thimersal, 0.5 percent wt./vol. BSA and 0.15 M NaCl. then each of five separate 0.] ml. aliquots of antiserum diluted respectively 1 to 5,000, l to 10,000, 1 to 20.000, 1 to 40,000 and l to 80,000 with a 0.04 M phosphate buffer at pH 7.4 containing 0.6 mM thimersal and 0.5 percent wt./vol. BSA and finally 0.] ml. of l-insulin were added.
  • the contents of the tubes were then mixed by inversion and the Z-gel fraction was separated by centrifugation at 1,000 X g for 5 minutes at room temperature. The supernatant was decanted and the pellet washed by resuspension in 10 ml. of ammonium acetate followed by recentrifugation. The supernatant was again decanted and the amount of l in the Z-gel pellet was measured.
  • EXAMPLE 5 g In order to test the accuracy of the assay, 2.5 uU of bovine insulin in 0.1 ml of an 0.04 M phosphate buffer at pH 7.4 containing 0.6 mM thimerosal, 0.5 percent wt./vol. BSA and 0.15 M NaCl were added to plasma samples in which the levels of immuno reactive insulin had been determined, using the assay of this invention, by the use of the standard inhibition curve. The assay was then repeated. The percent recovery was calculated by comparing the level ofimmunoreactive insulin in the samples before and after the addition of exogenous bovine insulin.
  • test fluid is blood plasma.

Abstract

A rapid radioimmunoassay for detecting immunoreactive insulin in body fluids, e.g., blood plasma, utilizing zirconyl phosphate gel at a pH at which free insulin will not bind to it, i.e., pH of 6.0 to 6.5, preferably 6.25, to adsorb antibody-bound insulin while leaving free insulin in solution, is disclosed.

Description

United States Patent Coffey et al.
[451 Feb. 18,1975
RADIOIMMUNOASSAY FOR INSULIN Inventors: John William Coffey, West Caldwell; Hans John Hansen, Allendale, both of NJ.
Assignee: Hoffmann-La Roche Inc., Nutley,
\ NJ. Filed: Mar. 9, 1973 Appl. No.: 339,803
U.S. Cl. 424/1, 23/230 B Int. Cl A6lk 27/04 Field of Search 424/1; 23/230 B References Cited UNITED STATES PATENTS 1/1971 Axen et a1. 424/1 3,646,346 2/1972 Catt 23/2308 3,697,638 10/1972 Hanson 424/1 OTHER PUBLICATIONS Moody et a1., Nuclear Science Abstracts, Vol. 20. No. 8, April 30, 1966, pp. 1564-1565, Item No. 12754.
Primary Examiner-Benjamin R. Padgett Attorney, Agent, or FirmSamuel L. Well [57] ABSTRACT 4 Claims, 2 Drawing Figures PAIENIEB FEB I 81975 CPM X10" IN Z-GEL PELLET CPM x 10- IN z-sa. PELLET DILUTION 0F ANTISERUM FIG. 1
4 I I I I I I I l MICROUNITS 0F INSULIN FIG 2 RADIOIMMUNOASSAY FOR INSULIN BACKGROUND OF THE INVENTION Various radioimmunoassays have been developed for the measurement of the level of immunoreactive insulin in the plasma of animals and humans. All the procedures depend on the competition between the endogenous insulin in body fluids, e.g., blood plasma, and exogenous radioactive insulin for the binding sites on anti-insulin antibodies.
Thus, Yalow et al., Journal of Clinical Investigation, 35, 1157 (1960) disclose a laborous process wherein paper electrophoresis is used to separate antibodybound insulin from free insulin. Morgan et al., Diabetes 12, 115 (1963), on the other hand, utilize the double antibody technique wherein anti-guinea pig y-globulin is used to precipitate the soluble complex formed between insulin and guinea pig anti-insulin antibody.
These known radioimmunoassays for measuring the level of immunoreactive insulin in body fluids, particularly in blood plasma are sufficiently accurate for the desired measurement but are relatively impractical since they require extended periods of time to complete and in some processes require the use of carriers for the antibody.
There is thus a need for a radioimmunoassay for measuring the level of immunoreactive insulin in the body fluids, e.g., blood plasma, spinal fluid, urine and the like, of animals and humans which is accurate, relatively rapid, economical and commercially practical.
The invention as described hereinafter provides such a radioimmunoassay.
SUMMARY OF THE INVENTION This invention relates to an improved radioimmunoassay for measuring the level of immunoreactive insulin in the body fluids, particularly blood plasma of animals and humans. More particularly, this invention relates to a radioimmunoassay for measuring immunoreactive insulin which can be completed within about three hours by utilizing zirconyl phosphate gel at a pH at which free insulin will not bind to it, i.e., at a pH of from 6.0.to 6.5, preferably 6.25, as the adsorbent for the insulin-antibody complex.
DETAILED DESCRIPTION OF THE INVENTION This invention is based upon the discovery that a radioimmunoassay for immunoreactive insulin in body fluids, preferably blood plasma can be completed within three hours when zirconyl phosphate gel (Z-gel) at a pH at which free insulin will not bind to it, i.e., at a pH of from 6.0 to 6.5, preferably pH 6.25 is used to adsorb antibody-bound insulin while leaving free insulin in solution.
The method is accurate and reproducible and eliminates the need for utilizing carriers to which the antibody is coupled. For example, the accuracy is shown by a comparison to a solid phase commercial assay using carriers having antibody coupled thereto. In the comparison thirty-two samples of human blood plasma were assayed for immunoreactive insulin using the solid phase commercial assay and using the assay of this invention. The results showed a statistically significant (p 0.01) coefficient of correlation between the two assays (0.998) indicating the assay of this invention is accurate. The reproducibility of the assay of this invention is within 10 percent when duplicate samples are run.
In conducting radioimmunoassays, procedures based on both the techniques of isotope dilution and sequential competitive-inhibition can be used. The preferred procedure for the detection of immunoreactive insulin according to this invention is the sequential competitive-inhibition method.
In this method a titration curve shown in FIG. 1 then a standard inhibition curve shown in FIG. 2 are developed.
The titration curve, used to determine the proper dilution of anti-insulin antiserum for used in the radioimmunoassay. This is necessary in order to avoid having excess antibody present, causing readings which are too high. The ideal is to have a dilution at which about half the labelled insulin is complexed with antiserum. The curve is prepared by adding increasing dilutions of the antiserum, diluted with a buffer composition at pH 7.4. A typical suitable buffer is composed of 0.04 M phosphate (prepared from NaH PO, and NaOH) containing 0.6 mM thimersal and 0.5 percent wt./vol. bovine serum albumin (BSA) to a constant amount of radioiodinated insulin I-insulin). A typical suitable buffer composition utilized in the incubation mixtures for preparing the titration curve is 0.2 ml. of a 0.04 M phosphate buffer at pH 7.4, containing 0.6 mM thimersal, 0.5 percent wt./vol. BSA and 0.15 M NaCl. The incubation buffer is mixed with 0.1 ml. of varying dilutions of the antiserum and 0.1 ml. l-insulin in an incubation test tube and the mixture is incubated at 37C. for 45 mins. The reaction is stopped by the addition of 5 ml. of an ammonium acetate slurry of Z-gel at pH 6.0 to 6.5, preferably 6.25, to each tube followed by 10 ml. of 0.1 M ammonium acetate, pH 6.25. The Z-gel slurry contains, on a volume basis, about 40-45 percent solids. The contents of the tubes are mixed, then centrifuged to separate the Z-gel-antibody-insulin precipitate and assayed for radioactivity. The proper dilution of antiserum is determined from the curve and utilized in subsequent assays utilizing the antiserum.
The standard inhibition curve is used to determine the concentration of insulin in the test fluid as follows:
Standard inhibition curves are prepared using mixtures containing 0.1 ml. of a buffer at pH 7.4. A typical buffer is composed of 0.04 M phosphate, containing 0.6 mM thimersal, 0.5 percent wt./vol. BSA and 0.15 M NaCl; 0.1 ml. of the appropriate dilution of antiserum and 0.1 ml. of a standard solution of bovine insulin, e.g., 1.0 to 10.0 uU in the same buffer. The mixture is incubated for 2 hours at 37C. then 0.1 ml. of I- insulin is added to each tube and incubated 45 minutes at 37C. The incubation is terminated by the addition of 5 ml. of an ammonium acetate slurry of Z-gel at a pH 6.0-6.5, preferably 6.25, solids content about 40-45 percent v/v, and 10 ml. of ammonium acetate at pH 6.25. The radioactivity is determined by centrifuging and assaying the resulting pellet for radioactivity.
0.1 MI. of blood plasma containing unknown amounts of insulin are treated in the same manner as the standards used to prepare the inhibition curve. The amount of insulin in the plasma samples is determined by comparison to the standard inhibition curve. If the plasma samples contain very high levels of insulin, they are diluted with appropriate amounts of a buffer at pH 7.4, preferably composed of 0.04 M phosphate, 0.6
mM thimersal and 0.5 percent wt./vol. BSA and then assayed.
In conducting the assay according to this invention, any inorganic buffer at pH 7.4 can be used provided its ionic strength is similar to that of the test fluid, e.g., blood plasma. Phosphate buffers are preferred because of their ready accessibility.
The following Examples illustrate the invention.
EXAMPLE 1 Preparation of Radioiodinated Insulin Twenty-five ug. of insulin (25 ,ul) in 0.4 M phosphate buffer (pH 7.4) was mixed with a mixture of 5 mCi of Na l in 50 pl. of dilute NaOH at pH 8-11 and 10 1.1.1. of 0.3 M phosphate buffer, pH 7.4.
100 pg. (10 pl.) of chloramine T (sodium-ptoluenesulfochloramine) in 0.05 M phosphate buffer, pH 7.4, was added to the reaction mixture to initiate the iodination reaction which was allowed to proceed at room temperature for 2 minutes, with constant shakmg.
The reaction was stopped by adding 200 pg. ,ul.) of sodium metabisulfite in 0.05 M phosphate buffer pH 7.4. Then 0.2 ml. of 1 percent aqueous bovine serum albumin was added. The mixture was chromatographed on a 2.5 X 20 cm. column of Sephadex G-25, a hydrophilic water-insoluble cross-linked dextran polymer gel commercially available from AB Pharmacia, Uppsala, Sweden, which had been equilibrated at 4C. with 0.1 M Tris.HCl buffer, pH 7.4, containing 0.9 percent NaCl.
The column was eluted with the same Tris buffer at a flow rate of 0.5 ml./min. and 1.0 ml. fractions were collected into tubes containing 1 ml. of 1 percent bovine serum albumin. The amount of radioactivity in a ul. aliquot of each fraction was determined and the fraction near the void volume of the column containing the largest amount of radioactivity was used as the source of l-insulin for the assay after dilution with a 0.04 M phosphate buffer at pH 7.4 containing 0.6 mM thimersal and 0.5 percent wt./vol. BSA until 1 ml of the diluted solution contains about-450,000 cpm/ml. of
EXAMPLE 2 Preparation of Zirconyl Phosphate Gel 100 Gm. of Zirconyl chloride SH O was dissolved in 15 liters of 0.1 M hydrochloric acid and the solution was vigorously stirred while 200 ml. of concentrated phosphoric acid was slowly added. The resulting gel was allowed to settle to about one-third of the original volume. The supernatant fluid was removed by aspiration. The gel was washed by adding distilled water to the gel to a volume of 15 liters; the gel was allowed to settle, and the supernatant fluid again removed by aspiration. This washing procedure was repeated five times. After the last washing, distilled water was added to a volume of 15 liters and enough concentrated acetic acid was added to make the gel slurry 0.1 M with respect to acetic acid. The gel was allowed to settle for 2 days in this solution after which the supernatant fluid was removed as completely as possible by aspiration. The Z-gel slurry remaining had a volume of approximately 3 to 4 liters and was adjusted to pH 6.25 with concentrated ammonium hydroxide. The resulting slurry contained, on a volume basis, about 40 to 45 percent solids.
EXAMPLE 3 Preparation of Titration Curve lnto five incubation test tubes 0.2 ml. of a 0.04 M phosphate buffer at pH 7.4 containing 0.6 mM thimersal, 0.5 percent wt./vol. BSA and 0.15 M NaCl. then each of five separate 0.] ml. aliquots of antiserum diluted respectively 1 to 5,000, l to 10,000, 1 to 20.000, 1 to 40,000 and l to 80,000 with a 0.04 M phosphate buffer at pH 7.4 containing 0.6 mM thimersal and 0.5 percent wt./vol. BSA and finally 0.] ml. of l-insulin were added.
The mixtures were then incubated at 37C. for 45 mins. The reaction was stopped by the addition of 5 ml. of a slurry of Z-gel, as prepared in Example 2, to each tube followed by the addition of 10 ml. of 0.1 M ammonium acetate at pH 6.25.
The contents of the tubes were then mixed by inversion and the Z-gel fraction was separated by centrifugation at 1,000 X g for 5 minutes at room temperature. The supernatant was decanted and the pellet washed by resuspension in 10 ml. of ammonium acetate followed by recentrifugation. The supernatant was again decanted and the amount of l in the Z-gel pellet was measured.
The results are shown in FIG. 1.
EXAMPLE 4 V H Preparation of Standard Inhibition Curve this time 0.1 ml. of l-insulin containing 43,000 cpm. I
were added and the mixtures incubated for an additional 45 minutes at 37C. The reaction was stopped by the addition of 5 ml. ofa Z-gel slurry as prepared in Example 2 and 10 ml. of ammonium acetate, pH 6.25. The'Z-gel fraction was separated and assayed for radioactivity as in Example 3. The results are shown in FIG. 2
EXAMPLE 5 g In order to test the accuracy of the assay, 2.5 uU of bovine insulin in 0.1 ml of an 0.04 M phosphate buffer at pH 7.4 containing 0.6 mM thimerosal, 0.5 percent wt./vol. BSA and 0.15 M NaCl were added to plasma samples in which the levels of immuno reactive insulin had been determined, using the assay of this invention, by the use of the standard inhibition curve. The assay was then repeated. The percent recovery was calculated by comparing the level ofimmunoreactive insulin in the samples before and after the addition of exogenous bovine insulin.
TABLE Patplasma sample +2.5 [.LU bovine insulin ient p.U insulin/ amount expected amount recovered No 0.1 ml. sample (pU) (uU) recovery I 1.45 3.95 4.15 108 2 1.75 4.25 3.95 88 3 1.95 4.25 4.35 96 4 1.20 3.70 3.35 86 5 1.35 3.85 4.25 116 6 2.35 4.85 4.80 98 7 1.60 4.10 3.85 90 8 3.70 6.20 5.50 72 9 4.40 6.90 6.00 64 I0 l.45(1/5)* 3.95 4.60 126 11 3.20 5.70 5.50 92 12 3.90 6.20 6.40 92 13 2.15( H40) 465 4.40 90 14 2.50( l/50) 5.00 4.20 68 15 2.45(1/50) 4.95 4.65 88 16 2.05 4.55 4.50 98 17 l.45(%) 3.95 4.40 118 18 3.90 6.40 6.85 H8 19 3.35 5.85 6.55 I28 20 1.40 3.90 3.80 96 21 1.85016) 4.35 4.90 122 22 3.50(%) 6.00 6.15 106 23 2.3506) 4.85 5.10 110 24 2.35 4.85 4.85 100 25 1.75 4.25 3.95 88 26 1.70(%) 4.20 4.55 114 27 2.0006) 4.50 5.35 134 28 2.35( /a) 4.85 4.90 102 29 2.30 4.80 4.60 92 30 2.75(1/10) 5.25 5.40 106 31 2.05( 4.55 4.70 106 The values in parentheses indicate the extent to which the plasma samples were diluted with an 0.04 M
phosphate buffer at pH 7.4 before the assay was done. "The mean percentage recovery was l00.4 17.0 (5.1).)
antibodyinsulin comple cand measuring the radioactivity thereof.
2. The radioimmunoassay of claim 1 wherein the pH of the zirconyl phosphate gel slurry is 6.25.
3. The radioimmunoassay of claim 1 wherein the zirconyl phosphate gel slurry contains on a volume basis about 40 percent to 45 percent solids.
4. The radioimmunoassay of claim 1 wherein the test fluid is blood plasma.

Claims (4)

1. IN A LIQUID PHASE RADIOIMMUNOASSAY FOR THE DETECTION OF IMMUNOREACTIVE INSULIN IN BLOOD PLASMA, THE IMPROVEMENT WHICH COMPRISES THE STEP OF ADDING A SLURRY OF ZIRCONYL PHOSPHATE GEL HAVING A PH OF FROM 6.0 TO 6.5 TO AN INCUBATION MIXTURE OF RADIOACTIVE INSULIN AND TEST FLUID TO STOP INCUBATION AND ADSORB ANTIBODY-BOUND INSULIN, SEPARATING THE ZIRCONYL PHOSPHATE GEL-BOUND INSULIN, SEPARATING THE ZIRCONYL RADIOCATIVITY THEREOF.
2. The radioimmunoassay of claim 1 wherein the pH of the zirconyl phosphate gel slurry is 6.25.
3. The radioimmunoassay of claim 1 wherein the zirconyl phosphate gel slurry contains on a volume basis about 40 percent to 45 percent solids.
4. The radioimmunoassay of claim 1 wherein the test fluid is blood plasma.
US339803A 1973-03-09 1973-03-09 Radioimmunoassay for insulin Expired - Lifetime US3867518A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US339803A US3867518A (en) 1973-03-09 1973-03-09 Radioimmunoassay for insulin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US339803A US3867518A (en) 1973-03-09 1973-03-09 Radioimmunoassay for insulin

Publications (1)

Publication Number Publication Date
US3867518A true US3867518A (en) 1975-02-18

Family

ID=23330670

Family Applications (1)

Application Number Title Priority Date Filing Date
US339803A Expired - Lifetime US3867518A (en) 1973-03-09 1973-03-09 Radioimmunoassay for insulin

Country Status (1)

Country Link
US (1) US3867518A (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4021534A (en) * 1975-12-12 1977-05-03 Hoffmann-La Roche Inc. Radioimmunoassay
US4038485A (en) * 1976-03-18 1977-07-26 Miles Laboratories, Inc. Test composition, device, and method
US4442218A (en) * 1981-05-27 1984-04-10 Corning Glass Works Method of measuring degree of partitioning
US4649043A (en) * 1982-03-22 1987-03-10 Alza Corporation Drug delivery system for delivering a plurality of tiny pills in the gastrointestinal tract
US5424402A (en) * 1993-10-18 1995-06-13 Board Of Trustees Of The University Of Kentucky Non-destructive method for radiolabelling biomolecules by halogenation
US20030054356A1 (en) * 2000-09-21 2003-03-20 Jacobson James W. Multiple reporter read-out for bioassays
US20060194345A1 (en) * 2003-08-29 2006-08-31 Kabushiki Kaisha Toshiba Concentration measuring method, concentration measuring kit, and sensor chip for use in the method
US20120100071A1 (en) * 2009-06-05 2012-04-26 John Valliant Synthesis and use of radiolabelled insulin analogues

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3555143A (en) * 1966-06-02 1971-01-12 Pharmacia Ab Method for the determination of proteins and polypeptides
US3646346A (en) * 1968-12-26 1972-02-29 Pharmacia Ab Antibody-coated tube system for radioimmunoassay
US3697638A (en) * 1970-06-01 1972-10-10 Hoffmann La Roche Antigens

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3555143A (en) * 1966-06-02 1971-01-12 Pharmacia Ab Method for the determination of proteins and polypeptides
US3646346A (en) * 1968-12-26 1972-02-29 Pharmacia Ab Antibody-coated tube system for radioimmunoassay
US3697638A (en) * 1970-06-01 1972-10-10 Hoffmann La Roche Antigens

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4021534A (en) * 1975-12-12 1977-05-03 Hoffmann-La Roche Inc. Radioimmunoassay
US4038485A (en) * 1976-03-18 1977-07-26 Miles Laboratories, Inc. Test composition, device, and method
US4442218A (en) * 1981-05-27 1984-04-10 Corning Glass Works Method of measuring degree of partitioning
US4649043A (en) * 1982-03-22 1987-03-10 Alza Corporation Drug delivery system for delivering a plurality of tiny pills in the gastrointestinal tract
US5424402A (en) * 1993-10-18 1995-06-13 Board Of Trustees Of The University Of Kentucky Non-destructive method for radiolabelling biomolecules by halogenation
US20030054356A1 (en) * 2000-09-21 2003-03-20 Jacobson James W. Multiple reporter read-out for bioassays
US7465540B2 (en) * 2000-09-21 2008-12-16 Luminex Corporation Multiple reporter read-out for bioassays
US20060194345A1 (en) * 2003-08-29 2006-08-31 Kabushiki Kaisha Toshiba Concentration measuring method, concentration measuring kit, and sensor chip for use in the method
US7498145B2 (en) * 2003-08-29 2009-03-03 Kabushiki Kaisha Toshiba Concentration measuring method, concentration measuring kit, and sensor chip for use in the method
US20120100071A1 (en) * 2009-06-05 2012-04-26 John Valliant Synthesis and use of radiolabelled insulin analogues

Similar Documents

Publication Publication Date Title
Heard et al. The action of lower aldehydes on the human erythrocyte
Tatarinov et al. Development of a radioimmunoassay for pregnancy‐specific beta1‐globulin and its measurement in serum of patients with trophoblastic and non‐trophoblastic tumours
US4108974A (en) Radioimmunoassay for thyroid hormone
US4299815A (en) Carcinoembryonic antigen determination
IE48481B1 (en) Diagnostic testing
Sato et al. Scurvy-prone animals, including man, monkey, and guinea pig, do not express the gene for gulonolactone oxidase
EP0119767B1 (en) Method of measuring ligands
US3867518A (en) Radioimmunoassay for insulin
EP0283779B1 (en) Method of assaying high molecular hyaluronic acid
GB1564456A (en) Radioimmunoassay for thyroid stimulating hormone
EP0103605B1 (en) Method for free ligand assays
GB1603406A (en) Assay of immune complexes
US4824777A (en) Method for determining thyroxine uptake
US4223002A (en) Isolation of alpha1 -fetoprotein
US3872225A (en) Process of viral diagnosis and reagent
Rehfeld et al. Radioimmunoassay for gastrin employing immunosorbent
US3505019A (en) Method for determining vitamin b12 and reagent therefor
Habermann et al. A rapid and simple radioimmunological procedure for measuring low concentrations of tetanus antibodies
Itzhaki et al. A study of the template properties of chromatin for DNA polymerase I and of the effects of ionising radiation
Wang et al. Salivary progesterone: Relation to total and non-protein-bound blood levels
Coffey et al. Radioimmunoassay for insulin
Moore Jr et al. A solid-phase radioimmunoassay for estrogen by estradiol-17β antibody covalently bound to a water insoluble synthetic polymer (enzacryl AA)
Grant et al. Use of radioactive antibodies for characterizing antigens and application to the study of flagella synthesis
Whitehead et al. Inhibition of viral hemagglutination by aggregated orosomucoid
US4195073A (en) Radioimmunoassay of alpha 1 fetoprotein